The U.S. Food and Drug Administration has approved the expanded label for the fluocinolone acetonide intravitreal implant (ILUVIEN) to include the treatment of chronic noninfectious uveitis affecting the posterior segment (NIU-PS) of the eye. This implant is also indicated for diabetic macular edema and is designed to provide continuous microdosing of fluocinolone acetonide. The approval enhances treatment options for patients with chronic NIU-PS and is expected to enhance supply security and access for appropriate patients in need.

Source: ANI Pharmaceuticals